Fierce Biotech June 29, 2022
Merck has begun taking applications for a new biotech accelerator program and is on the hunt for startups offering a special focus on artificial intelligence and machine learning.
The Merck Digital Sciences Studio (MDSS) aims to start with 12 participants in the early stages of development, with the drugmaker pledging to provide direct investments—including up to $150,000 in convertible notes—plus credits for access to cloud computing resources through the Microsoft for Startups program.
The inaugural dozen startups will go on to launch pilot programs of their technologies in collaboration with Merck’s researchers, including those tasked with uncovering new, potentially therapeutic molecules and designers of clinical trials.
Today's Sponsors
Today's Sponsor